Start-up developer Synosis Therapeutics has reached a deal with Roche to put a group of once-promising drug candidates back into the clinic. The deal gives Synosis control of five drug candidates that Roche had studied before halting development. The package includes four early-stage drugs targeting CNS diseases. Synosis will be responsible for clinical development of the drugs while Roche retains opt-in rights. Financial details were not disclosed.
- check out this press release
- here's the report on the deal from Pharma Times
Related articles:
Roche and Xenon ink pact on anemia therapies. Report
Epigenomics hit hard as Roche drops collaboration. Report